KORU Medical Systems Inc. (KRMD)
(Delayed Data from NSDQ)
$2.28 USD
-0.08 (-3.39%)
Updated May 17, 2024 04:00 PM ET
After-Market: $2.30 +0.02 (0.88%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KRMD 2.28 -0.08(-3.39%)
Will KRMD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for KRMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KRMD
KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates
KRMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
KORU Medical (KRMD) Forms New Deal on Subcutaneous Infusion
Silk Road Medical (SILK) Reports Q4 Loss, Tops Revenue Estimates
KORU Medical Systems Inc. (KRMD) Reports Q2 Loss, Tops Revenue Estimates
Other News for KRMD
REPRO-MED Systems (KRMD) Receives a Buy from Lake Street
KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic
Koru Medical signs supply agreement for Phase 3 trial
REPRO-MED Systems: Strong Start to Fiscal Year 2024 with Strategic Growth and Consistent Margins
Wall Street Analysts Are Bullish on Top Healthcare Picks